Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Abstract Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clinical study who received isatuximab at doses from 5 to 20 ...

Full description

Saved in:
Bibliographic Details
Main Authors: Fatiha Rachedi (Author), Kimiko Koiwai (Author), Nadia Gaudel‐Dedieu (Author), Bernard Sebastien (Author), Hoai‐Thu Thai (Author), Claire Brillac (Author), Jean Baptiste Fau (Author), Laurent Nguyen (Author), Helgi van de Velde (Author), Christine Veyrat‐Follet (Author), Dorothée Semiond (Author)
Format: Book
Published: Wiley, 2022-06-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items